Bibliography

• Aase, JM. Diagnostic dysmorfhology. Library of Congress: 1990
• AD Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, AL 35294-0006, USA.
• Adem C, Reynolds C, Ingle JN, Nascimento AG. Primary breast sarcoma: clinicopathologic series from the Mayo Clinic and review of the literature. Br J Cancer 2004; 91:237.
• Antiproteinuric therapy and fabry nephropathy: sustained reduction of proteinuria in patients receiving enzyme replacement therapy with agalsidase-beta.
• AUBennett RL, Hart KA, O'Rourke E, Barranger JA, Johnson J, MacDermot KD, Pastores GM, Steiner RD, Thadhani RSOJ Genet Couns. 2002;11(2):121.
• AUDesnick RJ, Brady R, Barranger J, Collins AJ, Germain DP, Goldman M, Grabowski G, Packman S, Wilcox WRSOAnn Intern Med. 2003;138(4):338.
• AUTahir H, Jackson LL, Warnock DGSOJ Am Soc Nephrol. 2007;18(9):2609.
• Branton MH, Schiffmann R, Sabnis SG et al. Natural history of Fabry renal disease: influence of alpha-galactosidase. A activity and genetic mutations on clinical course. Medicine (Baltimore) 2002; 81:122.
• Buyse, ML. Birth defects encyclopedia: the comprehensive, systematic, illustrated reference source for the diagnosis, delineation, etiology, biodynamics, occurence, prevention, and treatment of human anomalies of clinical relevance. Library of Congress: 1990
• Cassidy, SB. , Allanson, JE. Management of Genetic Syndromes – Second Edition. John Wiley & Sons, Inc., Publication: 2005
• Chen HC, Jen YM, Wang CH, et al. Etiology of vocal cord paralysis. ORL J Otorhinolaryngol Relat Spec 2007; 69:167.
• Chute CG, Greenberg ER, Baron J, et al. Presenting conditions of 1539 population-based lung cancer patients by cell type and stage in New Hampshire and Vermont. Cancer 1985; 56:2107.
• Colice GL. Detecting lung cancer as a cause of hemoptysis in patients with a normal chest radiograph: bronchoscopy vs CT. Chest 1997; 111:877.
• Department of Human Genetics, Box 1498, Mount Sinai School of Medicine, Fifth Avenue at 100th Street, New York, NY 10029, USA. rjd.fabry@mssn.edu
• Eng CM, Banikazemi M, Gordon RE et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am J Hum Genet 2001; 68:711.
• Eng CM, Guffon N, Wilcox WR, et al. Safety and efficacy of recombinant human alpha-galactosidase A--replacement therapy in Fabry's disease. N Engl J Med 2001; 345:9.
• Eyerounds.org, http://www.EyeRounds.org/cases/case29.htm
• Fabry disease in genetic counseling practice: recommendations of the National Society of Genetic Counselors.
• Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy.
• Franceschini G, Masetti R, D'Ugo D, et al. Synchronous bilateral Paget's disease of the nipple associated with bilateral breast carcinoma. Breast J 2005; 11:355.
• Hall, JG...[et al]. Handbook of physical measurements -2nd ed. 2007 - OUP
• Hirshberg B, Biran I, Glazer M, Kramer MR. Hemoptysis: etiology, evaluation, and outcome in a tertiary referral hospital. Chest 1997; 112:440.
• Hyde L, Hyde CI. Clinical manifestations of lung cancer. Chest 1974; 65:299
• Jones, KL. Smith padrões reconhecíveis de malformações congênitas. [revisão técnica Márcia Gonçalves Ribeiro; tradução Carlos André Oighenstein...et al]. Rio de Janeiro: Elsevier, 2007
• Jones, KL. Smith's Recognizable Patterns of Human Malformation. -6th ed. Elsevier, 2006
• Kuo CW, Chen YM, Chao JY, et al. Non-small cell lung cancer in very young and very old patients. Chest 2000; 117:354.
• Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast cancer. Br J Cancer 2005; 93:1046.
• Lidove O, Joly D, Barbey F et al, “Clinical Results of Enzyme Replacement Therapy in Fabry Disease: A Comprehensive Review of Literature”, Int J Clin Pract, 2007, 61(2):293-302. (PubMed 17263716)
• MacDermot KD, Holmes A, Miners AH. Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 98 hemizygous males. J Med Genet 2001; 38:750
• McGowan TS, Cummings BJ, O'Sullivan B, et al. An analysis of 78 breast sarcoma patients without distant metastases at presentation. Int J Radiat Oncol Biol Phys 2000; 46:383.
• Ramadan HH, Wax MK, Avery S. Outcome and changing cause of unilateral vocal cord paralysis. Otolaryngol Head Neck Surg 1998; 118:199.
• Ries M, Clarke J T, Whybra C et al, “Enzyme-Replacement Therapy With Agalsidase Alfa in Children With Fabry Disease,” Pediatrics, 2006, 118(3):924-32. [PubMed 16950982]
• Rosen PP, Kimmel M, Ernsberger D. Mammary angiosarcoma. The prognostic significance of tumor differentiation. Cancer 1988; 62:2145.
• Rosen, PP. Rosen's Brest Pathology - 3rd ed. 2009 by Lippincott Williams & Wilkins
• Schiffmann R, Kopp JB, Austin HA 3rd et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285:2743.
• Schiffmann R, Murray GJ, Treco D, et al. Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease. Proc Natl Acad Sci U S A 2000; 97:365.
• Schnitt SJ, Guidi AJ. Pathology of invasive breast cancer. In: Diseases of the Breast, 3rd, Harris JR, Lippman ME, Morrow M, Osborne CK (Eds), Lippincott, Williams and Wilkins, Philadelphia 2004. p.393.
• Spranger, JW. Bone dysplasias: an atlas of genetic disorders of skeletal development – 2nd ed. Oxford University Press: 2003
• Travis WD, Brambilla E, Müller-Hermelink HK. Pathology and Genetics: Tumours of the Lung, Pleura, Thymus and Heart, IARC, Lyon, France 2004.
• Wynbrandt, J, Ludman MD. The Encyclopedia of Genetic Disorders and Birth Defects – 3rd ed. Library of Congress: 2008
• Zelek L, Llombart-Cussac A, Terrier P, et al. Prognostic factors in primary breast sarcomas: a series of patients with long-term follow-up. J Clin Oncol 2003; 21:2583.
• Abnormal keratan sulphate excretion. Longdon K, Pennock CA Ann Clin Biochem. 1979;16(3):152.
• Department of Neurology, Jefferson Medical College, 1020 Locust St, Room 394, Philadelphia, PA 19107, USA.
• Hunter disease in a girl caused by R468Q mutation in the iduronate-2-sulfatase gene and skewed inactivation of the X chromosome carrying the normal allele. Sukegawa K, Song XQ, Masuno M, Fukao T, Shimozawa N, Fukuda S, Isogai K, Nishio H, Matsuo M, Tomatsu S, Kondo N, Orii T Hum Mutat. 1997;10(5):361. Department of Pediatrics, Gifu University School of Medicine, Japan.
• Insights into the diagnosis and treatment of lysosomal storage diseases.Wenger DA, Coppola S, Liu SL Arch Neurol. 2003;60(3):322.
• Molecular basis of mucopolysaccharidosis type II: mutations in the iduronate-2-sulphatase gene. Hopwood JJ, Bunge S, Morris CP, Wilson PJ, Steglich C, Beck M, Schwinger E, Gal A Hum Mutat. 1993;2(6):435. Department of Chemical Pathology, Women's and Children's Hospital, North Adelaide, South Australia.
• Morquio's disease and mucopolysaccharide excretion. Linker A, Evans LR, Langer LO. J Pediatr. 1970;77(6):1039.
• Mucopolysaccharidosis type II in females: case report and review of literature. Tuschl K, Gal A, Paschke E, Kircher S, Bodamer OA Pediatr Neurol. 2005;32(4):270. Department of General Pediatrics, University Children's Hospital Vienna, Austria.
• Neufeld EF, Muenzer J. The metabolic and molecular bases of inherited disease, Scriver C, Beaudet AL, Valle D, Sly W (Eds), McGraw-Hill, New York 2001. p.3421.
• Gompels MM, Lock RJ, Abinun M,et al. “C1 inhibitor deficiency: consensus document”. Clin Exp Immunol. 2005;139(3):379. Department of Immunology and Immunogenetics, North Bristol NHS Trust, Southmead Hospital, Bristol, UK.
• Bowen T, Cicardi M, Farkas H, Bork K,et al. “2010 International consensus algorithm for the diagnosis, therapy and management of hereditary angioedema”. Allergy Asthma Clin Immunol. 2010;6 (1): 24.
• Cicardi M and Zingale L. “How Do We Treat Patients With Hereditary Angioedema”. Transfus Apher Sci, 2003, 29(3):221-7.
• Farkas H, Jakab L, Temesszentandrasi G, et al. “Hereditary Angioedema: A Decade of Human C1-inhibitor Concentrate Therapy”. J Allergy Clin Immunol, 2007, 120(4):941-7.
• Frank MM and Jiang H. “New Therapies for Hereditary Angioedema: Disease Outlook Changes Dramatically”. J Allergy Clin Immunol, 2008, 121(1):272-80.
• Hermans C. “Successful Management with C1-Inhibitor Concentrate of Hereditary Angioedema Attacks During Two Successive Pregnancies: A Case Report”. Arch Gynecol Obstet, 2007, 276(3):271-6.
• Craig TJ, Levy RJ, Wasserman RL, et al. “Efficacy of human C1 esterase inhibitor concentrate compared with placebo in acute hereditary Angioedema attacks”. J Allergy Clin Immunol. 2009;124(4):801. Penn State University College of Medicine, Hershey, Pa., USA.
• Craig TJ, Bewtra AK, Bahna SL,et al. “C1 esterase inhibitor concentrate in 1085 Hereditary Angioedema attacks-final results of the I.M.P.A.C.T.2 study”. Allergy. 2011 Dec;66(12):1604-11. Epub 2011 Sep 2. Penn State University College of Medicine, Hershey, PA 17033, USA.
• Martinez-Saguer I, Rusicke E, Aygören-Pürsün E, et al. “Pharmacokinetic analysis of human plasma-derived pasteurized C1-inhibitor concentrate in adults and children with hereditary angioedema: a prospective study”. 2010;50(2):354. Centre of Paediatrics III, Department of Haematology, Oncology and Haemostasis, Comprehensive Care Centre for Thrombosis and Haemostasis, Johann-Wolfgang-Goethe-University Hospital, Frankfurt am Main, Germany.
• Agostoni A, Bergamaschini L, Martignoni G, et al. “Treatment of acute attacks of hereditary Angioedema with C1-inhibitor concentrate”. Allergy. 1980;44(5):299.
• Waytes AT, Rosen FS, Frank MMN. “Treatment of hereditary Angioedema with a vapor-heated C1 inhibitor concentrate”. Engl J Med. 1996;334(25):1630. Laboratory of Clinical Investigation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md, USA.
• Zingale LC, Pappalardo E, Zanichelli A, Cicardi M . “C1 inhibitor concentrate: efficacy and adverse reaction”. Int Immunopharmacol. 2002; 318:1385.
• Cicardi M, Zingale L. “How do we treat patients with hereditary angioedema”. Transfus Apher Sci. 2003;29(3):221. Department of Internal Medicine University of Milan, IRCCS Maggiore Hospital, Milan, Italy.
• Farkas H, Jakab L, Temesszentandrási G,et al. “Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy”. J Allergy Clin Immunol. 2007;120 (4):941. Semmelweis University, Faculty of Medicine, 3rd Department of Internal Medicine, Budapest, Hungary.
• Agostoni A, Aygören-Pürsün E, Binkley KE, et al. “Hereditary and acquired angioedema: problems and progress: proceedings of the third C1 esterase inhibitor deficiency workshop and beyond”. Allergy Clin Immunol. 2004;114(3 Suppl):S51.University of Milan, Italy.
• Cicardi M, Zingale LC, Zanichelli A, et al. “The use of plasma-derived C1 inhibitor in the treatment of hereditary angioedema”. Expert Opin Pharmacother. 2007;8(18):3173. University of Milan, Department of Internal Medicine, Ospedale L Sacco, Via G.B. Grassi 74, 20157 Milano, Italy.
• Cicardi M, Levy RJ, McNeil DL,et al. “Ecallantide for the treatment of acute attacks in hereditary angioedema”. N Engl J Med. 2010;363(6):523.
• Levy RJ, Lumry WR, McNeil DL, et al. “EDEMA 4: a phase 3, double-blind study of subcutaneous ecallantide treatment for acute attacks of hereditary angioedema”. Ann Allergy Asthma Immunol. 2010;104(6):523. Family Allergy&Asthma Center PC, Atlanta, Georgia 30342, USA.
• Icatibant. Deeks ED. Source Adis, a Wolters Kluwer Business, Auckland, New Zealand.http://emc.medicines.org.uk/medicine/21761/SPC/Firazyr (Accessed on Jully 22, 2012).
• Han Lee ED, Pappalardo E, Scafidi J, Davis AE. “Approaches toward reversal of increased vascular permeability in C1 inhibitor deficient mice”. 3rd Immunol Lett. 2003;89(2-3):155. Center for Blood Research, 800 Huntington Avenue, Boston, MA 02115, USA.
• Schneider L, Lumry W, Vegh A, Williams AH, Schmalbach T. “Critical role of kallikrein in hereditary Angioedema pathogenesis: a clinical trial of ecallantide, a novel kallikrein inhibitor”. J Allergy Clin Immunol. 2007;120(2):416. Children's Hospital, Division of Immunology, 300 Longwood Avenue, Boston, MA 02115, USA.
• Frank MM, Jiang H. “New therapies for hereditary angioedema: disease outlook changes dramatically”. J Allergy Clin Immunol. 2008; 121(1):272. Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710-0001, USA.
• http://saude.psicologiananet.com.br/falta-de-coordenacao-nos-movimentos-forca-e-equilibrio-–-sindrome-capos.html
• https://www.healthtap.com/#topics/juvenile-dermatomyositis
• http://commons.wikimedia.org/wiki/File:Dermatomyositis2.jpg
• http://www.gfmer.ch/genetic_diseases_v2/gendis_detail_list.php?cat3=1126